Patents by Inventor Jonathan Albert Back

Jonathan Albert Back has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FAB SIALYLATION OF ANTIBODIES
    Publication number: 20240067714
    Abstract: The present disclosure provides monoclonal antibodies (e.g., anti-TNF? antibodies) having Fab sialylation, and, in some aspects, Fab sialylation in combination with an afucosylated Fc. Such antibodies having improved immunogenicity profiles and related advantages. Such glycan modifications will improve current treatments and allow a better quality of life for patients. Accordingly, such monoclonal antibodies are useful for treating and preventing various diseases.
    Type: Application
    Filed: September 13, 2021
    Publication date: February 29, 2024
    Applicant: LIMMATECH BIOLOGICS AG
    Inventors: Manuela MALLY, Amirreza FARIDMOAYER, Rainer FOLLADOR, Jonathan Albert BACK
  • ANTIBODIES THAT BIND TO OX40 AND THEIR USES
    Publication number: 20220411526
    Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
    Type: Application
    Filed: June 30, 2022
    Publication date: December 29, 2022
    Inventors: Antoine ATTINGER, Stanislas BLEIN, Jonathan Albert BACK, Rami LISSILAA, Samuel HOU
  • Antibodies that bind to OX40 and their uses
    Patent number: 11407839
    Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: August 9, 2022
    Assignee: Ichnos Sciences SA
    Inventors: Antoine Attinger, Stanislas Blein, Jonathan Albert Back, Rami Lissilaa, Samuel Hou
  • ANTIBODIES THAT BIND TO TL1A AND THEIR USES
    Publication number: 20200079863
    Abstract: The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.
    Type: Application
    Filed: June 11, 2019
    Publication date: March 12, 2020
    Applicant: Glenmark Pharmaceuticals S.A.
    Inventors: Antoine ATTINGER, Jonathan Albert BACK, Stanislas BLEIN, Rami LISSILAA, Darko SKEGRO
  • Antibodies That Bind To OX40 and Their Uses
    Publication number: 20200071409
    Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
    Type: Application
    Filed: March 11, 2019
    Publication date: March 5, 2020
    Inventors: Antoine ATTINGER, Stanislas BLEIN, Jonathan Albert BACK, Rami LISSILAA, Samuel HOU
  • ANTIBODIES THAT BIND TO TL1A AND THEIR USES
    Publication number: 20180086840
    Abstract: The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.
    Type: Application
    Filed: May 8, 2017
    Publication date: March 29, 2018
    Applicant: Glenmark Pharmaceuticals S. A.
    Inventors: Antoine ATTINGER, Jonathan Albert Back, Stanislas Blein, Rami Lissilaa, Darko Skegro
  • Antibodies that Bind to OX40 and Their Uses
    Publication number: 20170260280
    Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
    Type: Application
    Filed: November 10, 2016
    Publication date: September 14, 2017
    Inventors: Antoine ATTINGER, Stanislas Blein, Jonathan Albert Back, Rami Lissilaa, Samuel Hou
  • Antibodies that bind to TL1A and their uses
    Patent number: 9290576
    Abstract: The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.
    Type: Grant
    Filed: January 2, 2014
    Date of Patent: March 22, 2016
    Assignee: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Antoine Attinger, Jonathan Albert Back, Stanislas Blein, Rami Lissilaa, Darko Skegro
  • ANTIBODIES THAT BIND TO TL1A AND THEIR USES
    Publication number: 20140308271
    Abstract: The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.
    Type: Application
    Filed: January 2, 2014
    Publication date: October 16, 2014
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: ANTOINE ATTINGER, JONATHAN ALBERT BACK, STANISLAS BLEIN, RAMI LISSILAA, DARKO SKEGRO
  • ANTIBODIES THAT BIND TO OX40 AND THEIR USES
    Publication number: 20140294824
    Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
    Type: Application
    Filed: March 21, 2014
    Publication date: October 2, 2014
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Antoine ATTINGER, Stanislas Blein, Jonathan Albert Back, Rami Lissilaa, Samuel Hou
  • Antibodies that bind to OX40 and their uses
    Patent number: 8748585
    Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
    Type: Grant
    Filed: July 10, 2012
    Date of Patent: June 10, 2014
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Antoine Attinger, Stanislas Blein, Jonathan Albert Back, Rami Lissilaa, Samuel Hou
  • Antibodies that bind to OX40 and their uses
    Publication number: 20130183315
    Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
    Type: Application
    Filed: July 10, 2012
    Publication date: July 18, 2013
    Applicant: Glenmark Pharmaceuticals S.A.
    Inventors: Antoine Attinger, Stanislas Blein, Jonathan Albert Back, Rami Lissilaa, Samuel Hou